Research programme: vitamin D analogues - Aphios

Drug Profile

Research programme: vitamin D analogues - Aphios

Alternative Names: 1,25(OH)2D3-3-BE; AMPI-109; APH-0701; APH-1201; APH-M109; MPI-105; MPI-106; MPI-107

Latest Information Update: 20 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boston University School of Medicine
  • Developer Aphios Corporation
  • Class Antineoplastics; Dihydroxycholecalciferols
  • Mechanism of Action Apoptosis stimulants; Calcitriol stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 20 Oct 2014 Active development in Prostate cancer (hormone refractory) (IV) is ongoing in the US
  • 22 Jun 2009 Preclinical development is ongoing
  • 20 Sep 2007 Aphios receives STTR grant from the National Cancer Institute for development of MPI 109 in hormone-refractory Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top